Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Gilla Kaplan Sells 15,000 Shares

Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Gilla Kaplan sold 15,000 shares of the business’s stock in a transaction that occurred on Friday, June 13th. The stock was sold at an average price of $10.31, for a total value of $154,650.00. Following the completion of the sale, the director now directly owns 44,623 shares in the company, valued at approximately $460,063.13. This represents a 25.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Gilla Kaplan also recently made the following trade(s):

• On Monday, June 16th, Gilla Kaplan sold 6,814 shares of Tyra Biosciences stock. The shares were sold at an average price of $10.38, for a total value of $70,729.32.
• On Thursday, June 12th, Gilla Kaplan sold 30,000 shares of Tyra Biosciences stock. The shares were sold at an average price of $10.31, for a total value of $309,300.00.

Tyra Biosciences Trading Down 2.0%

Shares of TYRA opened at $10.22 on Tuesday. The firm has a market cap of $542.58 million, a PE ratio of -6.35 and a beta of 1.07. The firm has a fifty day simple moving average of $9.63 and a two-hundred day simple moving average of $11.89. Tyra Biosciences, Inc. has a 1-year low of $6.42 and a 1-year high of $29.60.

Tyra Biosciences (NASDAQ:TYRA) last announced its earnings results on Thursday, May 8th. The company reported ($0.47) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.02. As a group, research analysts forecast that Tyra Biosciences, Inc. will post -1.57 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

TYRA has been the topic of several analyst reports. Piper Sandler initiated coverage on Tyra Biosciences in a research report on Wednesday, May 21st. They issued an “overweight” rating and a $33.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Tyra Biosciences in a research report on Monday, March 31st. Finally, Wedbush reaffirmed an “outperform” rating and issued a $30.00 price objective on shares of Tyra Biosciences in a research report on Friday, March 28th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $30.83.

Institutional Investors Weigh In On Tyra Biosciences

A number of hedge funds have recently added to or reduced their stakes in the stock. Rhumbline Advisers raised its stake in Tyra Biosciences by 4.1% during the 4th quarter. Rhumbline Advisers now owns 26,202 shares of the company’s stock valued at $364,000 after buying an additional 1,027 shares during the last quarter. American Century Companies Inc. increased its stake in shares of Tyra Biosciences by 5.8% in the 1st quarter. American Century Companies Inc. now owns 23,431 shares of the company’s stock worth $218,000 after purchasing an additional 1,289 shares in the last quarter. US Bancorp DE increased its stake in shares of Tyra Biosciences by 50.5% in the 1st quarter. US Bancorp DE now owns 5,435 shares of the company’s stock worth $51,000 after purchasing an additional 1,823 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new stake in shares of Tyra Biosciences in the 4th quarter worth $31,000. Finally, Bank of New York Mellon Corp increased its stake in shares of Tyra Biosciences by 5.2% in the 4th quarter. Bank of New York Mellon Corp now owns 45,007 shares of the company’s stock worth $626,000 after purchasing an additional 2,221 shares in the last quarter. 84.14% of the stock is currently owned by hedge funds and other institutional investors.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.